Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VLA1553

Phase 3Biologic

VValneva Austria GmbH

1

Indications

6

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chikungunya Virus InfectionActive, not recruiting

Chikungunya Virus InfectionPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q2 2031

Phase 3Active, not recruiting

Chikungunya Virus Infection

NCT04838444

Clinical

Trials by Indication[1]

Chikungunya Virus2 trials

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Completed·VValneva Austria GmbH·Phase 3·NCT04546724·4,128 enrolled

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Completed·VValneva Austria GmbH·Phase 1·NCT03382964·120 enrolled

Chikungunya Virus Infection2 trials

A Randomized, Observer-blinded, Dose Response Phase 2 Trial to Assess the Safety and Immunogenicity of Two Different Dose Levels of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years

Completed·VValneva Austria GmbH·Phase 2·NCT06106581·304 enrolled

An Open-Label, Single Arm Trial To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine (VLA1553) In Adults Aged 18 Years and Above

Active, not recruiting·VValneva Austria GmbH·Phase 3·NCT04838444·363 enrolled

Immunodeficiency1 trial

A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

Withdrawn·VValneva Austria GmbH·Phase 3·NCT06028841

Immunogenicity1 trial

A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

Withdrawn·VValneva Austria GmbH·Phase 3·NCT07133178

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for VLA1553. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VLA1553 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VLA1553. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valneva Austria GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: VValneva Austria GmbH

Related News